CA2914717C - Composes de 5,6,7,8-tetrahydropyrazino[2,3-c]pyridazine et leur utilisation dans le traitement de maladies oncologiques - Google Patents

Composes de 5,6,7,8-tetrahydropyrazino[2,3-c]pyridazine et leur utilisation dans le traitement de maladies oncologiques Download PDF

Info

Publication number
CA2914717C
CA2914717C CA2914717A CA2914717A CA2914717C CA 2914717 C CA2914717 C CA 2914717C CA 2914717 A CA2914717 A CA 2914717A CA 2914717 A CA2914717 A CA 2914717A CA 2914717 C CA2914717 C CA 2914717C
Authority
CA
Canada
Prior art keywords
alkyl
atoms
compounds
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2914717A
Other languages
English (en)
Other versions
CA2914717A1 (fr
Inventor
Germes Grigorievich CHILOV
Oleg Valentinovich STROGANOV
Viktor Sergeevich STROILOV
Fedor Nikolaevich NOVIKOV
Aleksey Alexandrovich ZEIFMAN
Ilya Yurievich TITOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
"NATIONAL PHARMACEUTICAL TECHNOLOGIES" LLC
"pharmenterprises" LLC
Original Assignee
"NATIONAL PHARMACEUTICAL TECHNOLOGIES" LLC
"pharmenterprises" LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by "NATIONAL PHARMACEUTICAL TECHNOLOGIES" LLC, "pharmenterprises" LLC filed Critical "NATIONAL PHARMACEUTICAL TECHNOLOGIES" LLC
Publication of CA2914717A1 publication Critical patent/CA2914717A1/fr
Application granted granted Critical
Publication of CA2914717C publication Critical patent/CA2914717C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
CA2914717A 2013-09-26 2014-06-30 Composes de 5,6,7,8-tetrahydropyrazino[2,3-c]pyridazine et leur utilisation dans le traitement de maladies oncologiques Expired - Fee Related CA2914717C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2013143520/04A RU2550346C2 (ru) 2013-09-26 2013-09-26 Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
RU2013143520 2013-09-26
PCT/RU2014/000478 WO2015047133A1 (fr) 2013-09-26 2014-06-30 Nouveaux composés chimiques, variantes, et leur utilisation pour traiter des maladies oncologiques

Publications (2)

Publication Number Publication Date
CA2914717A1 CA2914717A1 (fr) 2015-04-02
CA2914717C true CA2914717C (fr) 2017-03-28

Family

ID=52744082

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2914717A Expired - Fee Related CA2914717C (fr) 2013-09-26 2014-06-30 Composes de 5,6,7,8-tetrahydropyrazino[2,3-c]pyridazine et leur utilisation dans le traitement de maladies oncologiques

Country Status (10)

Country Link
US (1) US9695182B2 (fr)
EP (1) EP3050884B1 (fr)
JP (1) JP6372722B2 (fr)
KR (1) KR101854512B1 (fr)
CN (1) CN105492445B (fr)
AU (1) AU2014328837B2 (fr)
CA (1) CA2914717C (fr)
EA (1) EA028828B1 (fr)
RU (1) RU2550346C2 (fr)
WO (1) WO2015047133A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015110071A (ru) * 2015-03-23 2016-10-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО "ФармТех" Применение новых химических соединений (варианты) в качестве ингибиторов nuak1 киназы для лечения онкологических заболеваний
IT201600092051A1 (it) * 2016-09-13 2018-03-13 Alessandro Antonelli Composto medicale per il trattamento di tumori della tiroide
RU2631430C1 (ru) * 2016-10-26 2017-09-22 Общество С Ограниченной Ответственностью "Отечественные Фармацевтические Технологии" НОВЫЙ СПОСОБ СИНТЕЗА ПРОИЗВОДНЫХ ТЕТРАГИДРОПИРАЗИНО[2,3-c]ПИРИДАЗИНА
BR112020016234A2 (pt) * 2018-02-12 2020-12-15 Bayer Aktiengesellschaft Oxadiazóis fungicidas
WO2019243823A1 (fr) * 2018-06-21 2019-12-26 Curadev Pharma Limited Modulateurs azahétérocycliques à petites molécules de sting humain
KR102260995B1 (ko) * 2018-11-28 2021-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
US20230227474A1 (en) * 2019-03-15 2023-07-20 Skyhawk Therapeutics, Inc. Compositions and methods for correction of aberrant splicing

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2942001A (en) * 1956-11-16 1960-06-21 Ciba Pharm Prod Inc Piperazo-pyridazines
BE794200A (fr) * 1972-01-18 1973-05-16 Yoshitomi Pharmaceutical Famille de pyrido 4,3-a pyridazines, utilises comme medicaments
EP1089979A1 (fr) * 1998-06-26 2001-04-11 Du Pont Pharmaceuticals Company Quinoxalin-2(1h)-ones substitues utilises comme inhibiteurs de transcriptase inverse du vih
GB0000564D0 (en) * 2000-01-11 2000-03-01 Merck Sharp & Dohme Therapeutic agents
BR0307780A (pt) * 2002-02-19 2004-12-28 Ono Pharmaceutical Co Compostos derivados de piridazina fundida e medicamentos contendo os compostos como o ingrediente ativo
ES2401330T3 (es) 2003-02-26 2013-04-18 Sugen, Inc. Compuesto de heteroarilamino inhibidores de proteín quinasas
EP1648455A4 (fr) 2003-07-23 2009-03-04 Exelixis Inc Modulateurs de la proteine alk (anaplastic lymphoma kinase) et leurs methodes d'utilisation
RU2374248C9 (ru) * 2003-08-04 2010-05-20 Валерий Хажмуратович ЖИЛОВ Циклические биоизостеры производных пуриновой системы и их применение в терапии
MY147449A (en) 2003-08-15 2012-12-14 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
JP4989233B2 (ja) 2004-02-14 2012-08-01 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
US7973061B2 (en) 2004-03-31 2011-07-05 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7700592B2 (en) * 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
KR20080052611A (ko) * 2005-08-26 2008-06-11 메틸진 인크. 히스톤 탈아세틸 효소의 벤조디아제핀 및 벤조피페라진유도체 억제제
SI1959955T1 (sl) 2005-12-05 2011-02-28 Pfizer Prod Inc Postopek zdravljenja abnormalne celične rasti
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
ATE522249T1 (de) * 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
MX2010014171A (es) * 2008-06-19 2011-07-04 Xcovery Holding Co Llc Compuestos de piridazin-carboxamida sustituida como compuestos inhibidores de cinasa.
EP2365809B8 (fr) * 2008-11-12 2018-10-10 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines et dérivés utiles comme inhibiteurs de kinases
CA2747161C (fr) * 2008-12-19 2017-07-18 Abbott Laboratories (benzo[d]thiazol-2-ylcarbamoyl) 1,2,3,4-tetrahydroquinolines(hetero)arylsubstitue et composes associes et leurs utilisations pour le traitement du cancer et d'un exces de plaquettes
JP2013515734A (ja) * 2009-12-23 2013-05-09 エラン ファーマシューティカルズ，インコーポレイテッド ポロ様キナーゼの阻害薬としてのプテリジノン
US8916593B2 (en) * 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
JP6023062B2 (ja) 2010-10-08 2016-11-09 エックスカバリー ホールディング カンパニー エルエルシー 置換ピリダジンカルボキサミド化合物
WO2012097479A1 (fr) * 2011-01-21 2012-07-26 Abbott Laboratories Inhibiteurs bicycliques de la kinase des lymphomes anaplasiques
US9403800B2 (en) * 2012-01-24 2016-08-02 Chemregen, Inc. Compounds for inhibition of cancer cell proliferation

Also Published As

Publication number Publication date
CN105492445B (zh) 2018-02-13
KR20160037844A (ko) 2016-04-06
EP3050884A1 (fr) 2016-08-03
EA028828B1 (ru) 2018-01-31
AU2014328837A1 (en) 2015-12-24
JP6372722B2 (ja) 2018-08-15
WO2015047133A1 (fr) 2015-04-02
EA201501187A1 (ru) 2016-07-29
CN105492445A (zh) 2016-04-13
EP3050884A4 (fr) 2017-03-15
KR101854512B1 (ko) 2018-06-14
AU2014328837B2 (en) 2017-06-29
US20160200729A1 (en) 2016-07-14
RU2550346C2 (ru) 2015-05-10
CA2914717A1 (fr) 2015-04-02
RU2013143520A (ru) 2015-04-10
US9695182B2 (en) 2017-07-04
EP3050884B1 (fr) 2019-04-03
JP2016532719A (ja) 2016-10-20

Similar Documents

Publication Publication Date Title
CA2914717C (fr) Composes de 5,6,7,8-tetrahydropyrazino[2,3-c]pyridazine et leur utilisation dans le traitement de maladies oncologiques
KR102218333B1 (ko) Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
US7893059B2 (en) Thiazolopyrimidine PI3K inhibitor compounds and methods of use
US8987280B2 (en) Pyrazolopyrimidine PI3K inhibitor compounds and methods of use
US9522910B2 (en) Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon
JP5752232B2 (ja) プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
CA3158951A1 (fr) Derives d'aminoisoquinoleine substitues en position 4
CA3151355C (fr) Derive cyclique condense aromatique substitue et composition le comprenant et utilisation associee
IL234052A (en) Derivatives of 2-amino, 6-phenyl-conjugated pyrrolo [3,2-d] pyrimidine are useful as inhibitors of kinase raf
NO323766B1 (no) Azaindoler, farmasoytiske sammensetninger innbefattende og deres anvendelse for fremstilling av medikament
BR112013014914B1 (pt) Composto, composição farmacêutica e uso de um composto
CN102625807A (zh) 4-取代的吡啶-3-基-甲酰胺化合物和使用方法
TW200904819A (en) Substituted imidazo-and triazolopyrimidines
WO2010051549A1 (fr) Composés inhibiteurs de jak à la pyrazolopyrimidine et procédés
AU2009258115A2 (en) Diazacarbazoles and methods of use
IL297714A (en) Bicyclic kinase inhibitors and their uses
BRPI0721151A2 (pt) Composto ou um sal, solvato ou derivado farmaceuticamento aceitável do mesmo, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, métodos para a profilaxia ou um tratamento de um estado doentio ou de uma condição doentia mediado (a) por uma quinase fgfr e para a profilaxia ou o tratamento de câncer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160304

MKLA Lapsed

Effective date: 20200831